Levothyroxine Sodium Tablets Recalled for Subpotency
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 25 mcg, due to subpotency. The recall affects nationwide U.S. distribution of specific lot numbers.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall of a prescription drug where subpotency could lead to inadequate treatment of a serious medical condition. The rubric assigns Severe (score 4) to FDA Class II recalls with potential for significant health impact, and this recall involves a critical medication for thyroid function.
Plain-English summary
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), packaged in 10-tablet unit dose blisters per carton. The product is being recalled because it was found to be subpotent, meaning it may contain less of the active ingredient than labeled.
The recalled product was distributed nationwide in the United States. The affected lots are identified by bag lot numbers N02212A and N02212B, and blister lot number N02212, all with an expiration date of July 2026. The NDC carton number is 55154-3558-0 and the NDC blister number is 0904-6949-61.
Levothyroxine is a prescription medication used to treat thyroid hormone deficiency. Subpotent tablets may result in inadequate treatment of hypothyroidism, potentially leading to symptoms such as fatigue, weight gain, and other complications associated with insufficient thyroid hormone levels.
Consumers and healthcare providers should check the lot numbers and expiration dates of any Levothyroxine Sodium Tablets they have on hand. Anyone with affected product should contact their pharmacy or healthcare provider for a replacement. The recall was initiated on July 13, 2026, and the FDA was notified on July 17, 2026.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Major Pharmaceuticals
- Hazard
- subpotent-drug
- treatment-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Bag lot #: N02212A
- N02212B
- Exp. Date 07/2026
- Blister lot #: N02212
UPCs (1)
- 0055154356305
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighLevothyroxine Sodium Tablets Recalled for Subpotency by Major Pharmaceuticals
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency Nationwide
FDA (Drugs) · 2026-07-29
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Concerns
FDA (Drugs) · 2026-07-29
- SevereMajor Pharmaceuticals Recalls Levothyroxine Sodium Tablets Over Subpotency
FDA (Drugs) · 2026-07-29
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency
FDA (Drugs) · 2026-07-29
Same category
- SevereMajor Pharmaceuticals Recalls Levothyroxine Sodium Tablets Over Subpotency
FDA (Drugs) · 2026-07-29
- HighLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Concerns
FDA (Drugs) · 2026-07-29
- HighNaropin Injection Recall Over Particulate Matter Contamination
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- HighXylocaine Injection Recall Due to Hair Contamination
FDA (Drugs) · 2026-07-29